OverviewSuggest Edit

Erytech is a biopharmaceutical company developing innovative therapies to target unmet medical needs, particularly in the fields of cancer and orphan diseases. Erytech’s proprietary technology is based on encapsulation of therapeutic molecules into red blood cells. Encapsulation offers a number of benefits as compared to free-form compounds, reducing the potential for allergic reactions and allowing the therapeutic substance to remain longer in the body. The Company's product provides a therapeutic solution to patients with relapsed and refractory acute lymphoblastic leukemia.
TypePublic
Founded2004
HQLyon, FR
Websiteerytech.com

Latest Updates

Employees (est.) (Sept 2020)217
Revenue (FY, 2019)€5.3 M(+19%)
Share Price (Sept 2020)€5.2
Cybersecurity ratingAMore

Key People/Management at Erytech Pharma

Gil Beyen

Gil Beyen

CEO & Director
Jean-Paul Kress

Jean-Paul Kress

Director
Eric Soyer

Eric Soyer

Chief Financial Officer & Chief Operating Officer
Iman El-Hariry

Iman El-Hariry

Chief Medical Officer
Jérôme Bailly

Jérôme Bailly

Director of Pharmaceutical Operations and Qualified Person
Françoise Horand

Françoise Horand

Director of Research and Development Operations
Show more

Erytech Pharma Office Locations

Erytech Pharma has offices in Lyon, Cambridge and Princeton
Lyon, FR (HQ)
60 avenue Rockefeller
Cambridge, US
1 Main St #300
Princeton, US
104 Campus Dr
Show all (3)

Erytech Pharma Financials and Metrics

Erytech Pharma Revenue

Erytech Pharma's revenue was reported to be €5.28 m in FY, 2019
EUR

Revenue (FY, 2019)

5.3m

Net income (FY, 2019)

(62.7m)

EBIT (FY, 2019)

(64.1m)

Market capitalization (14-Sept-2020)

94.6m

Closing stock price (14-Sept-2020)

5.2

Cash (31-Dec-2019)

73.2m
Erytech Pharma's current market capitalization is €94.6 m.
EURFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

2.9m4.1m3.4m4.4m5.3m

Revenue growth, %

41%(19%)

General and administrative expense

7.7m6.8m8.8m

R&D expense

10.8m19.7m25.5m
EURFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

45.6m37.6m185.5m134.4m73.2m

Accounts Receivable

424.0k218.0k76.0k

Inventories

166.0k145.0k176.0k1.4m358.0k

Current Assets

51.9m42.5m191.6m149.9m81.6m
EURFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(15.0m)(21.9m)(33.5m)(38.2m)(62.7m)

Depreciation and Amortization

288.0k425.0k532.0k797.0k4.2m

Inventories

32.0k21.0k(31.0k)

Accounts Payable

1.6m1.2m3.2m
EURFY, 2015

Revenue/Employee

53.3k

Financial Leverage

1.1 x
Show all financial metrics

Erytech Pharma Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

Erytech Pharma Revenue Breakdown

Embed Graph

Erytech Pharma revenue breakdown by business segment: 94.7% from Research Tax Credit and 5.3% from Other Income

Erytech Pharma Online and Social Media Presence

Embed Graph

Erytech Pharma News and Updates

Global Acute Lymphocytic Leukemia Therapeutics Market 2018 | Major Kay Players – Erytech Pharma, Talon Therapeutic, Inc, Glaxosmithkline Plc, Sigma-tau Pharmaceuticals, Genzyme Corporation, Amgen, Bristol-myers Squibb, Novartis

WiseGuyRerports.com Presents “Global Acute Lymphocytic Leukemia Therapeutics Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023” New Document to its Studies Database Posted via Industry Today. Follow us on Twitter @IndustryToday

Erytech Pharma sets IPO pricing terms

Erytech Pharma, a French biopharmaceutical company, has priced its IPO of up to 4.26 million shares at between $23 and $24 per share. Erytech plans on listing the stock on the NASDAQ under the ticker symbol “ERYP.” Jefferies and Cowen & Company are among the underwriters. Erytech’s backers inclu…

Erytech Pharma Blogs

Monthly information related to total number of voting rights and shares composing the share capital – May 30, 2020

Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C – ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP)

ERYTECH’S COMBINED SHAREHOLDERS’ MEETING

Meeting held in closed session on June 26, 2020 Live webcast of the Shareholders’ Meeting Availability of the preparatory documents for the Shareholders’ Meeting Erytech Pharma (Euronext Paris and Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulat…

Erytech’s Combined Shareholders’ Meeting

Erytech’s Combined Shareholders’ Meeting Content Import Tue, 05/26/2020 - 16:00 Erytech’s Combined Shareholders’ Meeting May 26,2020 | Press Releases This release is a backfill from a News Wire Investor news Genera…

Monthly information related to total number of voting rights and shares composing the share capital – April 30, 2020

Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C – ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP)

ERYTECH Provides Business Update and Reports Cash Balance at End of Q1 2020

TRYbeCA-1 Phase 3 Trial: More than 75% of the planned~500 patients enrolled Fast-Drack designation granted by U.S. FDA Trial to continue as planned after third independent safety review Interim superiority analysis expected around year-end and final analysis in 2H of 2021 Cash position of € 58.6 mil…

ERYTECH engages in collaborative partnership with EU Horizon 2020 EVIDENCE consortium

ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced it will be part of EVIDENCE, a public-private consortium supported by the European Union in the framework …
Show more

Erytech Pharma Frequently Asked Questions

  • When was Erytech Pharma founded?

    Erytech Pharma was founded in 2004.

  • Who are Erytech Pharma key executives?

    Erytech Pharma's key executives are Gil Beyen, Jean-Paul Kress and Eric Soyer.

  • How many employees does Erytech Pharma have?

    Erytech Pharma has 217 employees.

  • What is Erytech Pharma revenue?

    Latest Erytech Pharma annual revenue is €5.3 m.

  • What is Erytech Pharma revenue per employee?

    Latest Erytech Pharma revenue per employee is €24.3 k.

  • Who are Erytech Pharma competitors?

    Competitors of Erytech Pharma include Vertex Pharmaceuticals, MyoKardia and Athersys.

  • Where is Erytech Pharma headquarters?

    Erytech Pharma headquarters is located at 60 avenue Rockefeller, Lyon.

  • Where are Erytech Pharma offices?

    Erytech Pharma has offices in Lyon, Cambridge and Princeton.

  • How many offices does Erytech Pharma have?

    Erytech Pharma has 3 offices.